Annual report pursuant to Section 13 and 15(d)

Loans Receivable - Components (Details)

v3.24.1
Loans Receivable - Components (Details) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Aug. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Total loans receivable   $ 8,968,000 $ 11,456,000  
Less allowance for expected credit losses   (7,902,000) (7,237,000)  
Loans receivable, net of expected credit losses   1,066,000 4,219,000  
Less current portion of loan receivable     (516,000)  
Loans receivable, long-term   1,066,000 3,703,000  
Teneo Fund SPVi LLC note        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Total loans receivable   5,622,000 5,911,000  
Pharma EU, LLC note        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Total loans receivable   1,410,000 1,410,000  
A&R note        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Total loans receivable   710,000 710,000  
SSZ and Elev8 note        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Total loans receivable   1,002,000 1,002,000  
Pure Hana Synergy note        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Total loans receivable   224,000 224,000  
Little Beach Harvest Note        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Total loans receivable   0 2,199,000  
Interest and Fee Income, Loans and Leases   0 $ 67,000  
Write off of loan receivable including both principal and accrued interest $ 5,135,000      
Interest rate on loans receivable       9.00%
Financing receivable, credit Loss, expense (reversal) $ 5,121,000 $ 665,000